Gok Yavuz Betul, Datar Saumil, Chamseddine Shadi, Mohamed Yehia I, LaPelusa Michael, Lee Sunyoung S, Hu Zishuo Ian, Koay Eugene J, Tran Cao Hop S, Jalal Prasun Kumar, Daniel-MacDougall Carrie, Hassan Manal, Duda Dan G, Amin Hesham M, Kaseb Ahmed O
Department of Medicine, University of Missouri, St. Louis, MO 63121, USA.
Department of Medicine, University of Texas at Houston, Houston, TX 77030, USA.
Cancers (Basel). 2023 Oct 7;15(19):4875. doi: 10.3390/cancers15194875.
The microbiome is pivotal in maintaining health and influencing disease by modulating essential inflammatory and immune responses. Hepatocellular carcinoma (HCC), ranking as the third most common cause of cancer-related fatalities globally, is influenced by the gut microbiome through bidirectional interactions between the gut and liver, as evidenced in both mouse models and human studies. Consequently, biomarkers based on gut microbiota represent promising non-invasive tools for the early detection of HCC. There is a growing body of evidence suggesting that the composition of the gut microbiota may play a role in the efficacy of immunotherapy in different types of cancer; thus, it could be used as a predictive biomarker. In this review, we will dissect the gut microbiome's role as a potential predictive and diagnostic marker in HCC and evaluate the latest progress in leveraging the gut microbiome as a novel therapeutic avenue for HCC patients, with a special emphasis on immunotherapy.
微生物群落在通过调节重要的炎症和免疫反应来维持健康和影响疾病方面起着关键作用。肝细胞癌（HCC）是全球癌症相关死亡的第三大常见原因，在小鼠模型和人体研究中均有证据表明，肠道微生物群通过肠道与肝脏之间的双向相互作用影响HCC。因此，基于肠道微生物群的生物标志物是早期检测HCC很有前景的非侵入性工具。越来越多的证据表明，肠道微生物群的组成可能在不同类型癌症的免疫治疗疗效中发挥作用；因此，它可用作预测性生物标志物。在这篇综述中，我们将剖析肠道微生物群作为HCC潜在预测和诊断标志物的作用，并评估利用肠道微生物群作为HCC患者新治疗途径的最新进展，特别强调免疫治疗。
